Table 1.
Baseline characteristics of participants. Values are numbers (percentages) unless stated otherwise
| Characteristic | Placebo (n=215) | Galantamine 24 mg (n=220) | Galantamine 32 mg (n=218) |
|---|---|---|---|
| Demography | |||
| Men/women | 83/132 | 81/139 | 80/138 |
| Mean (SD) age (years) | 72.7 (7.6) | 71.9 (8.3) | 72.1 (8.6) |
| Clinical | |||
| Mean (SD) weight (kg) | 67.2 (12.1) | 66.7 (12.8) | 66.2 (13.4) |
| No (%) of smokers | 193 (90) | 200 (91) | 199 (91) |
| Other active medical conditions | 154 (72) | 159 (72) | 168 (77) |
| No (%) with apolipoprotein E4 allele* | |||
| Homozygous | 34 (18) | 32 (17) | 27 (15) |
| Heterozygous | 83 (45) | 97 (53) | 95 (53) |
| Mean (SD) mini-mental state examination score | 19.3 (3.5) | 19.5 (3.4) | 19.0 (3.8) |
| Mean (SD) Alzheimer's disease assessment scale score† | 24.7 (9.3) | 25.4 (9.4) | 26.2 (10.4) |
| Mean (SD) disability assessment in dementia score | 66.6 (22.5) | 69.9 (21.4) | 69.6 (20.6) |
| Mean (SD) time since cognitive problem diagnosed (years) | 3.5 (2.3) | 3.6 (2.7) | 3.7 (2.2) |
| Mean (SD) time since probable Alzheimer's disease diagnosed (years) | 0.8 (1.0) | 0.9 (1.2) | 0.8 (1.0) |
| Brain imaging findings‡ | |||
| Territorial infarctions | 1 (0.5) | 7 (3) | 2 (1) |
| Lacunar infarctions | 17 (8) | 10 (5) | 16 (7) |
| White matter lesions | 0 | 0 | 2 (1) |
| Tumour | 0 | 1 (0.5) | 1 (0.5) |
*
n=185 for placebo, n=184 for galantamine 24 mg, and n=179 for galantamine 32 mg.
†
11 item cognitive subscale.
‡
Computed tomography or magnetic resonance imaging findings in past 12 months.